Top

Published in:

01-12-2015 | Gastrointestinal Oncology

A Long Non-coding RNA Activated by Transforming Growth Factor-β is an Independent Prognostic Marker of Gastric Cancer

Authors: Tomoko Saito, MD, Junji Kurashige, MD, PhD, Sho Nambara, MD, Hisateru Komatsu, MD, Hidenari Hirata, MD, Masami Ueda, MD, Shotaro Sakimura, MD, Ryutaro Uchi, MD, Yuki Takano, MD, Yoshiaki Shinden, MD, Tomohiro Iguchi, MD, PhD, Hidetoshi Eguchi, MD, PhD, Shogo Ehata, MD, PhD, Kazunari Murakami, MD, PhD, Keishi Sugimachi, MD, PhD, Koshi Mimori, MD, PhD

Published in: Annals of Surgical Oncology | Special Issue 3/2015

Abstract

Background

A recent study reported that long non-coding RNA activated by TGF-β (lncRNA-ATB) induced epithelial–mesenchymal transition (EMT) through the transforming growth factor-β (TGF-β)/miR-200s/ZEB axis in hepatocellular carcinoma. Herein, we focused on the clinical significance of lncRNA-ATB in gastric cancer (GC) patients.

Materials and Methods

Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) was performed to examine expression of lncRNA-ATB, miR-200b, and miR-200c in GC tissues (n = 183). Patients were divided into high and low lncRNA-ATB expression groups using a cutoff of lncRNA-ATB/GAPDH ≥0.60 or <0.60 to determine the clinicopathological significance of lncRNA-ATB in GC. Moreover, we evaluated the expression of TGF-β, lncRNA-ATB, miR-200s, and ZEB1 in GC cell lines by qRT-PCR. GC cell lines were treated by recombinant TGF-β1 or TGF-β receptor inhibitor to examine morphologic changes and genetic alterations, such as lncRNA-ATB, miR-200s, and ZEB1 levels, with respect to the EMT phenotype.

Results

The high lncRNA-ATB group experienced a lower overall survival rate compared with the low lncRNA-ATB group, and multivariate analysis indicated that lncRNA-ATB was an independent prognostic factor (hazard ratio 3.50; 95 % CI 1.73–7.44; p = 0.0004). miR-200c levels were lower and ZEB1 levels were higher in the high lncRNA-ATB group than in the low lncRNA-ATB group. Treatment with TGF-β in GC cell lines resulted in morphological EMT changes, upregulation of lncRNA-ATB and ZEB1, and downregulation of miR-200c and CDH1. SB431542 reduced lncRNA-ATB expression.

Conclusion

LncRNA-ATB plays an important role in EMT to promote invasion and metastasis through the TGF-β/miR-200s/ZEB axis, resulting in a poor prognosis in GC. LncRNA-ATB is a novel biomarker of lncRNA, indicative of a poor prognosis in GC patients.

Available only for authorised users

Nagini S. Carcinoma of the stomach: a review of epidemiology, pathogenesis, molecular genetics and chemoprevention. World J Gastrointest Oncol. 2012;4:156–69.PubMedPubMedCentralCrossRef

Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442–54.PubMedCrossRef

Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol. 2003;15:740–6.PubMedCrossRef

Gregory PA, Bert AG, Paterson EL, et al. The MiR-200 family and MiR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008;10:593–601.PubMedCrossRef

Wellner U, Schubert J, Burk UC, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol. 2009;11:1487–95.PubMedCrossRef

Yu J, Ohuchida K, Mizumoto K, et al. MicroRNA, Hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation. Mol Cancer. 2010;9:169.PubMedPubMedCentralCrossRef

Hur K, Toiyama Y, Takahashi M, et al. MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut. 2013;62:1315–26.PubMedPubMedCentralCrossRef

Liu XG, Zhu WY, Huang YY, et al. High expression of serum MiR-21 and tumor MiR-200c associated with poor prognosis in patients with lung cancer. Med Oncol. 2012;29:618–26.PubMedCrossRef

Cheng H, Zhang L, Cogdell DE, et al. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One. 2011;6:e17745.PubMedPubMedCentralCrossRef

10.

Kurashige J, Kamohara H, Watanabe M, et al. MicroRNA-200b regulates cell proliferation, invasion, and migration by directly targeting ZEB2 in gastric carcinoma. Ann Surg Oncol. 2012;19 Suppl 3:S656–64.PubMedCrossRef

11.

Burk U, Schubert J, Wellner U, et al. A reciprocal repression between ZEB1 and members of the MiR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008;9:582–9.PubMedPubMedCentralCrossRef

12.

Prensner JR, Chinnaiyan AM. The emergence of LncRNAs in cancer biology. Cancer Discov. 2011;1:391–407.PubMedPubMedCentralCrossRef

13.

Guttman M, Rinn JL. Modular regulatory principles of large non-coding RNAs. Nature. 2012;482:339–46.PubMedPubMedCentralCrossRef

14.

Tsai MC, Manor O, Wan Y, et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science. 2010;329:689–93.PubMedPubMedCentralCrossRef

15.

Gupta RA, Shah N, Wang KC, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010;464:1071–6.PubMedPubMedCentralCrossRef

16.

Matouk IJ, DeGroot N, Mezan S, et al. The H19 non-coding rna is essential for human tumor growth. PLoS One. 2007;2:e845.PubMedPubMedCentralCrossRef

17.

Liu XH, Sun M, Nie FQ, et al. Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging MiR-331-3p in gastric cancer. Mol Cancer. 2014;13:92.PubMedPubMedCentralCrossRef

18.

Shao Y, Chen H, Jiang X, et al. Low expression of LncRNA-HmlincRNA717 in human gastric cancer and its clinical significances. Tumour Biol. 2014;35(10):9591–5.PubMedCrossRef

19.

Wang Y, Zhang D, Wu K, Zhao Q, Nie Y, Fan D. Long non-coding RNA MRUL promotes ABCB1 expression in multidrug-resistant gastric cancer cell sublines. Mol Cell Biol. 2014;34:3182–93.PubMedPubMedCentralCrossRef

20.

Yuan JH, Yang F, Wang F, et al. A long noncoding RNA activated by TGF-beta promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell. 2014;25:666–81.PubMedCrossRef

21.

Kurokawa Y, Matsuura N, Kawabata R, et al. Prognostic impact of major receptor tyrosine kinase expression in gastric cancer. Ann Surg Oncol. 2014;21 Suppl 4:S584–90.PubMedCrossRef

22.

Hashiguchi Y, Nishida N, Mimori K, et al. Down-regulation of MiR-125a-3p in human gastric cancer and its clinicopathological significance. Int J Oncol. 2012;40:1477–82.PubMed

23.

Tan Z, Jiang H, Wu Y, et al. MiR-185 is an independent prognosis factor and suppresses tumor metastasis in gastric cancer. Mol Cell Biochem. 2014;386:223–31.PubMedCrossRef

24.

Gregory PA, Bracken CP, Smith E, et al. An autocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol Biol Cell. 2011;22:1686–98.PubMedPubMedCentralCrossRef

25.

Truong HH, Xiong J, Ghotra VP, et al. Beta1 integrin inhibition elicits a prometastatic switch through the TGFbeta-miR-200-ZEB network in E-cadherin-positive triple-negative breast cancer. Sci Signal. 2014;7:ra15.PubMedCrossRef

26.

Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15:178–96.PubMedPubMedCentralCrossRef

Title: A Long Non-coding RNA Activated by Transforming Growth Factor-β is an Independent Prognostic Marker of Gastric Cancer
Authors: Tomoko Saito, MD
Junji Kurashige, MD, PhD
Sho Nambara, MD
Hisateru Komatsu, MD
Hidenari Hirata, MD
Masami Ueda, MD
Shotaro Sakimura, MD
Ryutaro Uchi, MD
Yuki Takano, MD
Yoshiaki Shinden, MD
Tomohiro Iguchi, MD, PhD
Hidetoshi Eguchi, MD, PhD
Shogo Ehata, MD, PhD
Kazunari Murakami, MD, PhD
Keishi Sugimachi, MD, PhD
Koshi Mimori, MD, PhD
Publication date: 01-12-2015
Publisher: Springer US
Published in: Annals of Surgical Oncology / Issue Special Issue 3/2015
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-015-4554-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A Long Non-coding RNA Activated by Transforming Growth Factor-β is an Independent Prognostic Marker of Gastric Cancer

Abstract

Background

Materials and Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Materials and Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Special Issue 3/2015

When Does Neoadjuvant Chemotherapy Really Avoid Radiotherapy? Clinical Predictors of Adjuvant Radiotherapy in Cervical Cancer

Mitomycin C Pharmacokinetics as Predictor of Severe Neutropenia in Hyperthermic Intraperitoneal Therapy

Erratum to: Intratumor Textural Heterogeneity on Pretreatment 18F-FDG PET Images Predicts Response and Survival After Chemoradiotherapy for Hypopharyngeal Cancer

Oncoplastic Resection of Breast Cancers Located in the Lower-Inner or Lower-Outer Quadrant with the Modified McKissock Mammaplasty Technique

Shear-Wave Elastography for the Detection of Residual Breast Cancer After Neoadjuvant Chemotherapy

Prognostic Relevance of p53 Overexpression in Gastrointestinal Stromal Tumors of the Small Intestine: Potential Implication for Adjuvant Treatment with Imatinib